NCT07240337 Botulinum Toxin Applications in Hemiplegic Patients
| NCT ID | NCT07240337 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul Physical Medicine Rehabilitation Training and Research Hospital |
| Condition | Hemiplegia |
| Study Type | OBSERVATIONAL |
| Enrollment | 34 participants |
| Start Date | 2025-10-10 |
| Primary Completion | 2025-11-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 34 participants in total. It began in 2025-10-10 with a primary completion date of 2025-11-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This retrospective study will be conducted by reviewing the medical records of hemiplegic patients who received botulinum toxin treatment between 2017 and 2020 at the Physical Medicine and Rehabilitation outpatient clinic of Istanbul Physical Medicine and Rehabilitation Training and Research Hospital. A total of 35 hemiplegic patients who underwent botulinum toxin injection and had at least two follow-up records (with a 6-month interval) will be included. Sociodemographic and clinical data, stroke-related characteristics, botulinum toxin dosage, injected muscle groups, medications, and comorbidities will be recorded. Functional assessments, including the Functional Independence Measure (FIM) and Brunnstrom stage, as well as spasticity evaluations using the Modified Ashworth Scale and the Global Spasticity Index, will be obtained from patient files.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 75 years, clinically diagnosed with hemiplegia * Received botulinum toxin injection for upper and/or lower extremity spasticity * Availability of recorded data for two time points, including the Functional Independence Measure (FIM), Brunnstrom stage, Modified Ashworth Scale (MAS), Global Spasticity Index (GSI) * Documentation of injected muscles and total administered botulinum toxin dosage Exclusion Criteria: * Missing essential data (e.g., absence of FIM, MAS, GSI, or GAS at either visit) * Major interventions during the follow-up period such as surgery or initiation of intrathecal baclofen pump therapy * Severe concomitant neurological disorders (e.g., progressive neurodegenerative diseases) that interfere with assessment
Frequently Asked Questions
Who can join the NCT07240337 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hemiplegia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07240337 currently recruiting?
Yes, NCT07240337 is actively recruiting participants. Visit ClinicalTrials.gov or contact Istanbul Physical Medicine Rehabilitation Training and Research Hospital to inquire about joining.
Where is the NCT07240337 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07240337 clinical trial?
NCT07240337 is sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital. The trial plans to enroll 34 participants.